How sponsors of orphan drugs can take advantage of paediatric expertise at the PDCO

Rare diseases raise a critical planning consideration for sponsors: how to manage the inclusion of a paediatric population. This can be particularly challenging due to factors such as limited patient numbers, ethical considerations in trial design for children, and the need for age-appropriate formulations. Around 75% of rare diseases largely affect a paediatric population, which […]